Drug Profile

NRT YHD 001

Alternative Names: NRT-YHD-001; NRT-YHD_001

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NEORNAT
Class Antineoplastics; Antisense RNA; MicroRNAs
Mechanism of Action MicroRNA inhibitors; Thrombospondin 1 expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Liver cancer

Most Recent Events

03 Jul 2025 Preclinical trials in Liver cancer in South Korea (IV), prior to April 2025
25 Apr 2025 NEORNAT anticipates the regulatory approval submissions to the Ministry of Food and drug safety (MFDS) South Korea and the US FDA in the second quarter of 2025 (NEORNAT pipeline, April 2025)
25 Apr 2025 NEORNAT plans a phase I trial in Liver cancer, in the third quarter of 2025 (NEORNAT pipeline, April 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com